Purpose The Radiation Therapy Oncology Group (RTOG) conducted a randomized, placebo-controlled trial evaluating the efficacy of GM-CSF in reducing mucosal injury and symptom burden from curative radiotherapy for head and neck (H&N) cancer. Methods Eligible patients with H&N cancer receiving radiation encompassing C50 % of the oral cavity or oropharynx received subcutaneous GM-CSF or placebo. Quality of life (QoL) was assessed using the RTOG-modified University of Washington H&N Symptom Questionnaire at baseline 4, 13, 26, and 48 weeks from radiation initiation.
Introduction
External beam radiation treatment is an important component of curative therapy for many patients with head and neck carcinoma. Acute oropharyngeal mucositis is the most common complication of radiation treatment for head and neck carcinoma [1] . Increased use of intensive altered fractionation radiation treatment regimens and concurrent chemotherapy for the treatment for head and neck cancer has increased the frequency and severity of this morbidity. Oropharyngeal mucositis can be extremely painful, requiring narcotic pain medication and limiting oral intake. For some patients, mucositis symptoms become a dose-limiting toxicity, interrupting or halting radiation treatment [2] . The resulting radiation treatment break may hinder local tumor control and survival [3] . In addition, if the mucosal injury becomes severe enough, it may weaken the mucosal barrier and promote infection that has the potential to cause additional symptoms or be lifethreatening, especially if the patient is neutropenic as a result of systemic therapies [4] . Oropharyngeal mucositis and other consequences of head and neck cancer radiation therapy cause significant symptoms. The resultant pain, thick mucous, swallowing and chewing difficulty, disfigurement, dehydration, and weight loss are known to affect health-related quality of life (QoL) from the patient's perspective [5] [6] [7] .
Pilot studies suggested granulocyte-macrophage colony-stimulating factor (GM-CSF) may reduce the incidence and severity of mucositis in patients with head and neck carcinoma [8] [9] [10] . It was hypothesized that GM-CSF would thereby relieve symptoms in patients undergoing radiation therapy for head and neck cancer. Radiation Therapy Oncology Group (RTOG) 99-01 was a prospective, double-blind, placebo-controlled phase III trial designed to determine whether concomitant delivery of GM-CSF in patients undergoing curative radiation for head and neck cancer reduced radiation-induced oropharyngeal mucosal injury and radiation-induced symptom burden. This manuscript reports the impact of concomitant GM-CSF on symptom relief as it relates to patient-reported QoL.
Materials and methods

Eligibility criteria
Adult patients with a histologically confirmed diagnosis of head and neck carcinoma were eligible for enrollment in RTOG 99-01 if the radiation port (either definitive or postoperative) encompassed 50 % of the oral cavity, oropharynx, or both. Patients with cervical nodal metastases from an unknown primary were eligible for enrollment if C50 % of the salivary gland dose was C50 Gy. The protocol permitted prior surgery, induction chemotherapy, and concurrent cisplatin. Patients with T1-T2 glottic tumors, Karnofsky performance scores (KPS) less than 60, idiosyncratic response to GM-CSF, or residual oropharyngeal mucosal injury from chemotherapy were excluded. Additional exclusion criteria have been previously published [11] .
The study was reviewed and approved by the Institutional Review Board at the participating institutions. Written informed consent was obtained in all patients prior to randomization.
Pretreatment evaluation
Pretreatment evaluation included complete history and physical examination, biopsy of primary tumor or nodal diagnosis of an unknown primary tumor, diagram of lesion and nodes, and computed tomography of the oral cavity and oropharynx.
Randomization and treatment details
This placebo-controlled, double-blind trial randomized patients to receive radiation and GM-CSF, 250 lg/m 2 , or radiation and placebo using permuted block randomization. Patients were stratified according to the administration of concurrent cisplatin. The GM-CSF or placebo subcutaneous injections started one week prior to initiation of radiation and stopped two weeks after radiation completion. Details of study drug administration and radiation therapy have been previously described [11] . The protocol required administration of the study drug on Monday, Wednesdays, and Fridays, within 2 h after each radiation fraction. The doses were held on the days patients were scheduled to receive chemotherapy. No more than one out of six consecutive doses of the study drug could be missed during radiation. If concurrent chemotherapy was administered, patients could miss no more than 2 out of 6 consecutive doses. Opposed photon portals were required for radiation therapy with inclusion of C50 % of the oral cavity and/or oropharynx to ensure inclusion of adequate visible mucosa.
Oral and oropharyngeal mucosa received a central axis midplane dose of 60-70 Gy over 6-7 weeks, using standard fractionation of 1.8-2 Gy once a day.
The use of the following oral care medications was prohibited during radiation therapy: amifostine, chlorhexidine gluconate, sucralfate tablets or slurry, benzydamine hydrochloride rinses, and selective decontamination of the oral cavity.
Patient-reported quality of life assessment QoL was prospectively measured using the RTOG-modified University of Washington Head and Neck Symptom Questionnaire (UWHNSS). It contains components of the UWHNSS and additional questions assessing pain and mucous (Appendix Fig. 2 ). The UWHNSS is a selfadministered, validated instrument designed for head and neck cancer patients with varying tumor sites and stages that has demonstrated responsiveness to clinical change [12] . The RTOG-modified UWHNSS contains the employment question from UWHNSS version 1, all questions in UWHNSS version 3 except for shoulder disability [13] , and additional questions assessing mouth pain, throat pain, mucous amount, and mucous consistency. The question stems for the additional questions are modeled after the question stems for the UWHNSS. Each question has five levels of functioning (Likert scale), ranging from no dysfunction to total dysfunction (Appendix Fig. 2 ). For each question, patients were instructed to circle the statement that best describes their level of function during the past week. The maximum (worst) score was 100 corresponding to total dysfunction, and the minimum (best) score was 20 corresponding to no dysfunction. The RTOGmodified UWHNSS was administered prior to radiation therapy and four, 13, 26, and 48 weeks after the initiation of radiation therapy. Most patients ([80 %) completed their assessment at the appointment. Other methods of completion were by mail and telephone.
Factor analysis of the RTOG-modified UWHNSS has identified four factors derived from 11 items: (1) mucus (amount of mucus or phlegm and consistency of mucous or phlegm); (2) eating (swallowing, amount of saliva, consistency of saliva, and taste); (3) pain (general pain, mouth pain, and throat pain); and (4) activities (activity and recreation/entertainment). The RTOG-modified UWHNSS total symptom score uses the 11 items retained by the factor analysis. We report individual question scores, factor domain scores, and total symptom score.
Provider evaluation of mucositis and toxicity
An objective site-specific mucosal injury scoring system (Appendix Table 7 ) and the National Cancer Institute Cooperative Group Common Toxicity Criteria (NCI-CTC, version 2.0, March 1998) (Appendix Table 8 ) were used for provider assessment of mucosal injury, as previously described [11] . Visual assessment of treatment-induced mucosal damage was performed pretreatment, three times a week during the course of radiation, and 2 weeks after the completion of radiation. Patients were evaluated weekly for acute radiation and drug toxicity; toxicity was scored by the NCI-CTC, version 2.0.
Statistical considerations
Descriptive statistics were generated to characterize the study cohort. Patients who completed the RTOG-modified UWHNSS were compared to those who did not complete it. Respondents in the GM-CSF and placebo arms were compared at each time point. Fisher's exact test was used to compare categorical variables. Wilcoxon-Mann-Whitney test and t Test were used to compare continuous variables. RTOG-modified UWHNSS factor domain and total symptom scores were averaged using all items answered by the patient (not limiting it to complete cases only). Since the individual items are ordinal and factors are not normally distributed, the two-sided Wilcoxon-MannWhitney test using the normal approximation was used to assess differences between arms. Total score, however, is approximately normally distributed so a two-sided t test was used to test for differences.
Per protocol, the primary QoL end point was change in QoL from baseline to 13 weeks [12] . Change scores were calculated by subtracting the follow-up assessment from baseline (baseline-follow-up). A negative change score corresponds to increased symptom burden at follow-up, while a positive change score corresponds to reduced symptom burden at follow-up. Change in individual question scores, factor domain scores, and total symptom score was evaluated from 4 through 48 weeks. An analysis of the primary outcome (change in QoL from baseline to 13 weeks) was also performed on the subset of patients who completed treatment per protocol or with an acceptable variation. Graphs with 95 % confidence intervals were constructed to illustrate change in factor scores and total score over time for all patients.
Potential floor and ceiling effects for deterioration status were evaluated using a 5-point score change that was prespecified in the protocol. Due to the high number of ceiling effects, deterioration was evaluated as decline versus no decline since many patients were unable to improve.
A linear fixed-effect model, using maximum likelihood as the method of estimation, was built for the total symptom score and each domain score. Baseline score, time (baseline, 4, 13, 26, and 48 weeks), and treatment arm were forced into the model as covariates. Time-by-treatment interaction, KPS (=100 vs. \100), smoking status (current/ past smoker vs. never smoked), age, primary disease site (pharynx vs. oral cavity vs. larynx), concurrent cisplatin (yes vs. no), oral supplements at study entry (yes vs. no), and feeding tube at study entry (yes vs. no) were considered for inclusion in the model using a p value cut-off of \0.1.
Spearman's correlation coefficient was used to evaluate correlation between provider visually assessed mucositis and factor domains and total scores at 4 and 13 weeks. For all analyses, to adjust for multiplicity while accounting for the correlated nature of the items and domains, alpha = 0.01 was used when testing the 15 items individually and the 4 domains. An alpha = 0.05 was used when testing all other comparisons. All data were analyzed with SAS (v9.2 for Windows, SAS institute, Cary, NC).
At time of protocol design, it was decided a priori that a 5-point change would be a meaningful score change. Based on the two-sample t test with equal variances, a sample size of 120 patients would ensure at least 90 % statistical power to detect a treatment difference of 5 points in the mean change scores (SD 8.5) at the 0.05 significance level (two-sided).
Results
Quality of life compliance
One hundred thirty patients were accrued from 2000 to 2002, of which five were clinically ineligible. One hundred and fourteen (91 %) out of 125 eligible patients completed at least 1 of 5 questionnaires. Baseline compliance was 82 % and then was consistently lower throughout followup; 78, 68, 60, and 51 % of patients completed assessments at 4, 13, 26, and 48 weeks, respectively. Completion was similar between arms at each time point (Table 1) except for 48 weeks. At 48 weeks, more patients in the placebo arm completed the assessment (p = 0.007); however, there were no differences in pretreatment characteristics in 48-week completers between treatment arms (p [ 0.05). Patient demographics, clinical characteristics, and provider assessment of mucositis during treatment were not significantly different (p [ 0.05) between those who did and did not complete any questionnaires. Similarly, patient demographics, clinical characteristics, and provider assessment of mucositis during treatment were not significantly different (p [ 0.05) between the patients who did (n = 77) and did not (n = 48) contribute to the primary outcome, change in QoL at week 13. Thus, a missing at random mechanism can be assumed and minimal bias anticipated.
Patient's baseline characteristics
The majority of analyzable patients were male (73 %), had an oropharyngeal or oral cavity tumor (68 %), did not receive cisplatin (88 %), and were not using oral supplements (85 %) or a feeding tube (79 %) at study entry (Table 2) . Their mean age was 59 years. Fifty-three of the 103 patients who completed the baseline questionnaire were randomized to receive GM-CSF. Patient demographics and clinical characteristics were well balanced between treatment arms (Table 2) . Patients reported that employment, chewing, and general pain were the most burdensome symptoms domains at baseline (Table 3) . Baseline total symptom score, pain domain score, eating domain score, activities domain score, and most individual item scores were well balanced between treatment arms (p [ 0.05 total symptom score, p [ 0.01 domains and individual items, Table 3 ). There was a trend toward higher ) were well balanced between the GM-CSF (n = 37) and placebo (n = 40) arms. There was a trend toward higher baseline amount of mucous (p = 0.0251) and mucous domain (p = 0.0279) symptom burden in GM-CSF patients.
GM-CSF effect on symptom burden and quality of life
The protocol-specified QoL primary end point was change in QoL at the end of the acute period (13 weeks). At 13 weeks, patients in the placebo and GM-CSF arms had a The maximum (worst) score was 100 corresponding to total dysfunction, and the minimum (best) score was 20 corresponding to no dysfunction negative change in mean total symptom score, indicating increase in symptom burden relative to baseline (-20.8 placebo, -18.4 GM-CSF). There were no detectable differences in mean change in total symptom score or in median change in pain domain score, eating domain score, activity domain score, and most individual item scores at 13 weeks (p [ 0.05 total symptom score, p [ 0.01 domains and individual items, Table 4 ). Similarly, there were no detectable differences in mean change in total symptom score or in median change in pain domain score, eating domain score, activity domain score, and most individual item scores at the 4-, 26-, and 48-week time points (Table 4 ). There was a trend toward increased amount of mucous symptom burden in the placebo group relative to the GM-CSF group at 4 weeks (median -20 It should be noted that although the protocol called for a sample size of 120 patients, only 77 patients were evaluated for the primary outcome resulting in 72 % statistical power. Figure 1 illustrates trends in domain scores and total symptom score over time with 95 % confidence intervals. The figures show baseline QoL decrements, a deterioration of QoL during treatment, and subsequent partial improvement for all domains and for total score. Given potential difference in baseline QoL between patients in the GM-CSF and placebo arms, multivariate analyses evaluated the impact of GM-CSF on QoL during follow-up while controlling for baseline scores and patient's characteristics (Table 5 ). Baseline pain domain score (p = 0.007), activities domain score (p \ 0.001), eating domain score (p = 0.012), and total symptom score (p = 0.006) did impact subsequent scores. The positive baseline score effect estimates for these domains and for the total symptom score indicate subsequent increased symptom burden in patients who had higher baseline symptom burden. In contrast, baseline mucous domain score did not impact subsequent mucous domain score (p = 0.18). After controlling for baseline QoL scores and other covariates, there was no difference in mucous (p = 0.78), pain (p = 0.66), activities (p = 0.26), or eating (p = 0.89) domain scores, and no difference in total score (p = 0.83) between patients in the GM-CSF and placebo arms. There were negative time effect estimates for all four domains (mucous, pain, activities, and eating, p \ 0.05) and for the total score (p \ 0.001), indicating decreased symptom burden over follow-up time in patients receiving head and neck cancer radiation therapy.
Floor and ceiling effects were evaluated for each domain and for total symptom score. Only three patients had mucous domain ''floor effects'' indicating they were unable to decline due to experiencing the worst symptom burden at baseline. ''Ceiling effects'' were present for some patients in all four domains and the total symptom score. These patients were unable to improve because they had no symptom burden at baseline. Ceiling effects were not concerning because all patients received head and neck radiation therapy, which is known to increase symptom burden. However, symptom deterioration was evaluated at each time point, and there were no significant differences in proportion to patients reporting deterioration versus no deterioration between treatment arms at any follow-up time point.
Analysis of patients who completed treatment per protocol
The GM-CSF drug supply ended before all the patients completed therapy, and a proportion of patients discontinued the drug due to toxicity. Therefore, a separate analysis was performed in patients who completed treatment per protocol or with an acceptable protocol deviation. Patient demographics, clinical characteristics, and provider assessment of mucositis during treatment were not significantly different between analyzable patients for QoL (43 patients in the GM-CSF group and 49 patients in the placebo group) who completed treatment per protocol or with an acceptable deviation. Baseline total symptom score (p = 0.18), all domain scores (p [ 0.01), and most individual item scores (p [ 0.01) were also well balanced between treatment arms in the per-protocol patients. Patients receiving GM-CSF reported higher amount of mucous (40 vs. 20 ; p = 0.008) than placebo patients. The 70 per-protocol patients analyzed for change in QoL at 13 weeks had worse provider assessment of mucositis during treatment (mucosal injury tool median 1.4 [0-5.4] vs. 1.1 [0-5.5]; p = 0.03) and a different distribution of primary disease than the 24 per-protocol patients that did not have sufficient data for analysis. The 37 GM-CSF and 40 placebo per-protocol patients analyzed for change in QoL at 13 weeks had similar distributions of patient demographics and clinical characteristics. Total symptom score, all domain scores, and most individual item scores were well balanced between the arms. Patients receiving GM-CSF reported higher amount of mucous symptom burden (p = 0.010) than placebo patients. There were no detectable differences in mean change in total symptom score, or in median change in pain domain score, eating domain score, activity domain score, and most individual item scores at all time points (p [ 0.05 total symptom score, p [ 0.01 domains and individual items). Table 2) . Patient-reported QoL domains during the acute phase (4-and 13-week time points) were compared to provider visual assessment of worst acute mucositis. Patient-reported mucous domain, eating domain, and total symptom score did not correlate with provider visual assessment of mucositis by NCI-CTC or with physician visual assessment of mucositis by the site-specific mucosal injury scoring system (Table 6 ). Provider assessment of mucositis by NCI-CTC was correlated with patient-reported pain domain and eating domain at 4 weeks (r = 0.2361, p = 0.0251 and r = 0.2116, p = 0.0478, respectively). Provider assessment of mucositis by the site-specific mucosal injury scoring was not correlated with patientreported pain and eating domains.
Discussion
In this prospective, double-blind, placebo-controlled phase III trial, concomitant delivery of GM-CSF in patients undergoing curative radiation for head and neck carcinoma did not improve patient-reported radiation-induced symptom burden as measured by the RTOG-modified University of Washington Head and Neck Symptom Questionnaire. Patients in both the GM-CSF and placebo arms reported baseline QoL decrements, deterioration of QoL during treatment, and subsequent partial improvement in QoL for all domains and for total symptom score; however, there was no difference in change in QoL between patients in the GM-CSF and placebo arms. Only patient-reported pain and eating at 4 weeks were weakly correlated with physician visual assessment of worst mucositis. Patient-reported mucous, eating, and total symptom burden did not correlate with physician visual assessment of worst mucositis. RTOG 99-01 is distinct from other studies addressing the utility of GM-CSF in this population as it is a large randomized trial and other studies did not include formal patient-reported assessments [9, 10, 14] . At the end of this study's acute period (13 weeks), symptom burden Table 4 continued
Change from baseline to 4 weeks
Change from baseline to 13 weeks was considered significant for total score Change scores were calculated by subtracting the follow-up assessment from baseline (baseline-follow-up). Therefore, a negative change score corresponds to increased symptom burden at follow-up increased from baseline within both the GM-CSF and placebo arms, but there were no differences in change in symptom burden from baseline between the two treatment arms except for a slight difference in the mucus domain. However, this difference did not persist on multivariate analysis and may have reflected the higher baseline mucous symptoms present in the GM-CSF arm. At subsequent time points, there continued to be no significant QoL differences between the two study groups through 48 weeks. Clinical trials that evaluate interventions to relieve or prevent the often debilitating toxicities of head and neck cancer treatment frequently depend on physician evaluation of patient symptoms by the NCI-CTC. We previously reported that GM-CSF did not significantly reduce the severity or duration of treatment-induced mucositis as measured by provider visual assessment in RTOG 9901 [11] . The fact that provider assessment of mucositis toxicity during the acute period was only weakly correlated with patient-reported pain and eating and did not correlate with patient-reported symptom burden during the same timeframe in this trial highlights the importance of assessing patient-reported outcomes in symptom intervention trials. Patient's self-assessment can differ substantially from the healthcare provider's judgment [15, 16] . For example, a RTOG phase III study evaluating amifostine for mucosal protection in lung cancer patients treated with chemoradiation found striking differences between physician-rated NCI-CTC and patient's self-assessment [17] . There was no difference in the primary outcome of the study, NCI-CTC Grade 3 esophagitis, between the treatment arms. However, patient-reported swallowing on both the QoL measure and the patient's daily diary improved with amifostine. Conversely, in two randomized, placebocontrolled trials evaluating palifermin in patients undergoing chemoradiation for head and neck carcinoma, palifermin decreased provider-graded oral mucositis but did Fig. 1 Total symptom score (a), mucous domain score (b), pain domain score (c), eating domain score (d), and activities domain score (e) from baseline through 48 weeks after start of radiation therapy (RT) for patients in the placebo and GM-CSF arms. The maximum (worst) score was 100 corresponding to total dysfunction, and the minimum (best) score was 20 corresponding to no dysfunction. Bars represent 95 % confidence intervals not impact patient-reported mouth and throat soreness [18, 19] . Therefore, it is of paramount importance to include patient-reported end points on symptom intervention trials [20] . The longitudinal QoL and patient-reported symptoms for patients receiving radiation for head and neck cancers documented in this study are similar to trends reported in other studies, with baseline QoL decrements, a deterioration of QoL during treatment, and subsequent partial improvement [5, 7] . The QoL symptom burden observed in this study at baseline including mouth and throat pain, change in chewing and swallowing function, altered taste, change in mucous, and inability to perform normal activities has been observed in other studies evaluating comparable patients [6, 21] .
Potential limitations deserve further consideration. First, a large portion of patients enrolled in RTOG 9901 did not complete the symptom questionnaire. Patients appeared to be missing at random, but there may have been unaccounted differences between patients in the GM-CSF and placebo arms. Second, although the protocol called for a sample size of 120 patients, only 77 were evaluated for the primary end point; therefore, the lack of difference between GM-CSF and placebo may have been a result of insufficient sample size. Finally, the GM-CSF drug supply ended before all the patients completed therapy and a proportion of patients discontinued the drug due to toxicity. However, analysis of patients treated per protocol or with acceptable study deviation reached similar conclusions.
Despite these potential limitations, the lack of benefit of GM-CSF on patient-reported symptom burden in addition to the previously reported lack of benefit of GM-CSF on physician-assessed visible mucositis suggests GM-CSF does not prevent or treat head and neck radiation-induced symptoms. Given the considerable morbidity associated with radiation-induced mucositis, continued efforts are needed to identify interventions that prevent or diminish this debilitating toxicity. Future symptom intervention trials should include patient-reported end points since physician perception of mucositis can differ from patient perception of symptom burden. 
